Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Fusaroli

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Frontiers in Pharmacology|December 12, 2024
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guidelineMichele Fusaroli, Francesco Salvo, Charles Khouri, et al.
BMJ (Clinical Research Ed.)|November 3, 2022
Transparency and robustness of safety signalsCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Clinical Pharmacology and Therapeutics|May 30, 2023
Interpretation of Pharmacovigilance Disproportionality AnalysesCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Drug Safety|December 11, 2025
Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality AnalysisMichele Fusaroli, Joseph Mitchell, Annette Rudolph, et al.
Drug Safety|August 31, 2023
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative ApproachValentina Giunchi, Michele Fusaroli, Manfred Hauben, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Drug Safety|October 15, 2025
Correction: Charting and Sidestepping the Pitfalls of Disproportionality AnalysisMichele Fusaroli, Daniele Sartori, Eugène P van Puijenbroek, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Drug Safety|August 27, 2020
Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from PharmacovigilanceEmanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Frontiers in Pharmacology|December 12, 2024
The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guidelineMichele Fusaroli, Francesco Salvo, Charles Khouri, et al.
BMJ (Clinical Research Ed.)|November 3, 2022
Transparency and robustness of safety signalsCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Clinical Pharmacology and Therapeutics|May 30, 2023
Interpretation of Pharmacovigilance Disproportionality AnalysesCharles Khouri, Michele Fusaroli, Francesco Salvo, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Expert Opinion on Drug Safety|June 24, 2024
The evolving role of disproportionality analysis in pharmacovigilanceMichele Fusaroli, Emanuel Raschi, Elisabetta Poluzzi, et al.
Drug Safety|December 11, 2025
Causal Inference Tools for Pharmacovigilance: Using Causal Graphs to Identify and Address Biases in Disproportionality AnalysisMichele Fusaroli, Joseph Mitchell, Annette Rudolph, et al.
Drug Safety|August 31, 2023
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative ApproachValentina Giunchi, Michele Fusaroli, Manfred Hauben, et al.
Cancers|April 30, 2021
Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting SystemEmanuel Raschi, Michele Fusaroli, Andrea Ardizzoni, et al.
Drug Safety|October 15, 2025
Correction: Charting and Sidestepping the Pitfalls of Disproportionality AnalysisMichele Fusaroli, Daniele Sartori, Eugène P van Puijenbroek, et al.
Pageof 6